HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru,Journal of the International AIDS Society

当前位置： X-MOL 学术 › J. Int. AIDS Soc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru
Journal of the International AIDS Society ( IF 4.6 ) Pub Date : 2019-11-01 , DOI: 10.1002/jia2.25411
William L Trebelcock ₁ , Javier R Lama ₂ , Ann Duerr _{1,

3} , Hugo Sanchez ₄ , Robinson Cabello ₅ , Trupti Gilada _{3,

6} , Patricia Segura ₂ , Sari L Reisner _{7,

8} , Kenneth H Mayer _{7,

8} , James Mullins ₁ , Rachel A Bender Ignacio _{1,

3}

Affiliation

Transmitted, or any pretreatment drug resistance (TDR, PDR) can compromise efficacy of first‐line antiretroviral therapy (ART). In Peru, genotypic resistance testing is not routinely performed before ART initiation, and estimated PDR prevalence prior to 2012 ranged from 1.0% to 4.7%. We aimed to update estimates of PDR prevalence in men who have sex with men (cis‐MSM) and transgender women (TW).

中文翻译：

秘鲁利马顺性别男男性行为者和跨性别女性对艾滋病毒预处理的耐药性

传播或任何治疗前耐药（TDR、PDR）都会影响一线抗逆转录病毒治疗（ART）的疗效。在秘鲁，在 ART 开始前不常规进行基因型耐药性检测，估计 2012 年之前的 PDR 流行率为 1.0% 至 4.7%。我们旨在更新男男性行为者 (cis-MSM) 和跨性别女性 (TW) 中 PDR 患病率的估计值。

更新日期：2019-11-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11